FRANKLIN LAKES, N.J., June 3, 2013 /PRNewswire/ -- BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the launch of BD Neopak™, a new glass prefillable syringe system specifically engineered for the administration of biopharmaceutical injectable drugs. This new product is designed to address industry challenges in developing, manufacturing and marketing biologic drugs to patients.
The BD Neopak™ Glass Prefillable Syringe provides biopharmaceutical companies and patients with an even higher level of quality and enhanced container and device integration. Developed with a quality-by-design approach, the product is manufactured in a fully indexed process, which eliminates glass-to-glass contact resulting in fewer visual defects and increased glass strength. The new process reduces silicone levels while maintaining the appropriate glide force functionality. Through tighter dimensional tolerances and by limiting the dead volume space, the BD Neopak™ Glass Prefillable Syringe also reduces waste and overfilling of the biologic drug.
"In today's environment, regulatory authorities, patients and prescribers demand higher quality and more reliability in injectable drug delivery systems," said Claude Dartiguelongue, President, BD Medical – Pharmaceutical Systems. "The BD Neopak™ Glass Prefillable Syringe is designed to reduce risks associated with primary container and drug interactions and enable our customers' drug products speed to market safely and effectively."
Seven of the top 10 selling drugs worldwide and more than half of drugs currently in development are biologics.[i] To support drug development with the BD Neopak™ Glass Prefillable Syringe, BD offers customers a full range of drug compatibility assessment services, drug and system-related functional requirements and regulatory expertise for registration support for the product.
The BD Neopak™ Glass Prefillable Syringe also offers further customization options for pharmaceutical partners with sensitive drugs through BD XSi™ cross-linked silicone technology (which reduces sub-visible particles while maintaining syringe functionality) and ultralow tungsten technology. Furthermore, BD's advances in needle technology improve the patient experience and ensure reliable flow mechanics with more viscous drug formulations.[ii]
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
[i] EvaluatePharma (June 2012).
[ii] Data on file at BD
|SOURCE BD-Becton Dickinson|
Copyright©2012 PR Newswire.
All rights reserved